Document is current
Any future updates will be listed below
-
Authors
Betschel, Stephen D.
Chapdelaine, Hugo
Gagnon, Remi
Goodyear, M. Dawn
Keith, Paul K.
El-Zoeiby, Ahmed
Khutoryansky, Natalie
Castaner, Daniel N.
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03845400 at ClinicalTrials.govDocuments that mention this clinical trial
Long-term effectiveness and safety of lanadelumab in Canadian patients with hereditary angioedema: a subanalysis of the EMPOWER study
https://doi.org/10.1186/s13223-025-01007-9
Sustained Effectiveness, Tolerability, and Safety of Long-Term Prophylaxis with Lanadelumab in Hereditary Angioedema: The Prospective, Phase 4, Noninterventional EMPOWER Real-World Study
https://doi.org/10.1007/s12325-025-03226-3
-
Funding
Funding for this research was provided by:
Takeda Development Center Americas, Inc., Lexington, MA, USA.
- License Information
-
More Information
Article History
Received: 3 July 2025
Accepted: 3 December 2025
First Online: 21 January 2026
Declarations
:
: This protocol was approved by the ethics committees of the participating sites. The study was performed according to the ethical principles of the Declaration of Helsinki, the International Council for Harmonization Good Clinical Practice Guidelines, and the requirements of the public registration of clinical trials. Written informed consent was obtained prior to participation in the study.
: Not applicable.
: SDB has been a speaker and/or received advisor fees from Astria Therapeutics, BioCryst, CSL Behring, Ionis, KalVista Pharmaceuticals, Pharvaris, and Takeda; and received research funding from CSL Behring and Takeda. HC has been a speaker and/or received advisor fees from Alexion, CSL Behring, Novartis, Pharming, and Takeda; and received research funding within the last 2 years (Principal Investigator) from Alexion, CSL Behring, GSK, KalVista Pharmaceuticals, Merck, Novartis, Pharvaris, Sanofi, Sobi, and Takeda. RG reports site research at ALK-Abelló, AstraZeneca, DBV Technologies, GSK, Moderna, Novartis, Regeneron, and Sanofi; consultancy for ALK-Abelló, Bausch+Lomb, Regeneron, and Sanofi-Genzyme; and has received speaker fees from Bausch+Lomb and Novartis. MDG has been a speaker and/or received advisor fees from Alexion, BioCryst, CSL Behring, Medison, Pfizer, Sanofi, Sobi, and Takeda; and has received research funding from Takeda. PKK has received research funding/honoraria from CSL Behring and Takeda; and advisory board/speaker fees from ALK-Abelló, AstraZeneca, Bausch+Lomb, BioCryst, CSL Behring, GSK, Medexus Pharmaceuticals, Novartis, Sanofi, Takeda, and Valeo Pharma. AE-Z is an employee of Takeda Canada, Inc., and holds stock/options in Takeda Pharmaceutical Company Limited. NK is an employee of Cytel, contracted by Takeda Development Center Americas, Inc. DNE is an employee of Takeda Development Center Americas, Inc., and holds stock and/or share options in Takeda Pharmaceutical Company Limited.
